These pioneering studies on the balance between Teffs and Tregs suggest that an increased number of tumor-infiltrating Teffs, rather than the depletion of Tregs may be used to predict sensitivity to anti-CTLA-4 immunotherapy. The gene discussed is CTLA4; the disease is neoplasm.